Cytomegalovirus (CMV) is characterized by lifelong latent infection following primary infection. Prevalence of viral carriage in adult populations is high. Infections with CMV in immunocompetent persons are usually asymptomatic, but in the immunocompromised patient, primary infection or reactivation of latent infection may be severe.
Efalizumab is a humanized monoclonal antibody that blocks lymphocyte activation and migration. We describe herein a case of CMV infection occurring in a patient with psoriasis who was undergoing efalizumab therapy.
Miquel FJ, Colomina J, Maríi JI, Ortega C. Cytomegalovirus Infection in a Patient Treated With Efalizumab for Psoriasis. Arch Dermatol. 2009;145(8):961-962. doi:10.1001/archdermatol.2009.154